MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
MUSTANG BIO, INC. (MBIO)
MUSTANG BIO, INC. (MBIO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable and accrued exp...
Stock-based compensation expense...
Payable and accrued expenses - r...
Prepaid expenses and other asset...
Negative Cash Flow Breakdown
Net loss
Proceeds from issuance of common...
Settlement of payables
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,072
-955
-538
-468
Issuance of common shares - equity fee on equity offerings to fortress biotech
0
0
0
179
Common shares issuable - annual stock dividend to fortress biotech
-
-
273
-
Research and development - licenses acquired
-
-
0
-
Stock-based compensation expenses
21
22
23
23
Depreciation expense
0
0
0
0
Amortization of operating lease right-of-use assets
0
0
0
0
Settlement of payables
33
76
731
577
Loss on disposal of property and equipment
-
-
0
0
Asset impairment
-
-
0
0
Gain on lease termination
0
0
0
0
Prepaid expenses and other assets
-2
-3
-50
-12
Other receivables
0
0
0
0
Accounts payable and accrued expenses
96
-20
-769
-12
Payable and accrued expenses - related party
19
18
-26
25
Deferred income
-
-
0
-
Lease liabilities
0
0
0
0
Net cash used in operating activities
-967
-1,008
-1,718
-818
Proceeds from the sale of property and equipment
0
0
0
0
Net cash from investing activities
0
0
0
0
Proceeds from issuance of common shares, net of offering costs - equity offering
0
0
0
0
Proceeds from issuance of common shares, net of offering costs - at-the-market offering
-141
0
0
0
Proceeds from warrant exercises
-
-
0
7,145
Proceeds from issuance of common shares under espp
-
-
0
0
Net cash (used in) provided by financing activities
-141
0
0
7,145
Net change in cash and cash equivalents
-1,108
-1,008
-1,718
6,327
Cash and cash equivalents, beginning of the period
16,258
17,266
18,984
6,839
Cash and cash equivalents, end of the period
15,150
16,258
17,266
18,984
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
MBIO Cash Flow Sankey Diagram
Sankey diagram visualizing MBIO cash flow for the period
Net change in cash
and cash...
-$1,108K
(-119.04%↓ Y/Y)
Accounts payable and
accrued expenses
$96K
(108.07%↑ Y/Y)
Stock-based compensation
expenses
$21K
(-74.70%↓ Y/Y)
Payable and accrued
expenses - related party
$19K
(111.66%↑ Y/Y)
Prepaid expenses and
other assets
-$2K
(92.86%↑ Y/Y)
Net cash used in
operating activities
-$967K
(64.55%↑ Y/Y)
Net cash (used in)
provided by financing...
-$141K
(-101.91%↓ Y/Y)
Canceled cashflow
$138K
Net loss
-$1,072K
(-17.16%↓ Y/Y)
Proceeds from issuance of
common shares, net of...
-$141K
(-123.54%↓ Y/Y)
Settlement of payables
$33K
(-95.85%↓ Y/Y)
Buy us a coffee